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Galectin-3 (Gal-3) is the only chimeric protein in the galectin family. Gal-3 structure
comprises unusual tandem repeats of proline and glycine-rich short stretches bound
to a carbohydrate-recognition domain (CRD). The present review summarizes Gal-3
functions in the extracellular and intracellular space, its regulation and its internalization
and secretion, with a focus on the current knowledge of Gal-3 role in central nervous
system (CNS) health and disease, particularly oligodendrocyte (OLG) differentiation,
myelination and remyelination in experimental models of multiple sclerosis (MS).
During myelination, microglia-expressed Gal-3 promotes OLG differentiation by binding
glycoconjugates present only on the cell surface of OLG precursor cells (OPC). During
remyelination, microglia-expressed Gal-3 favors an M2 microglial phenotype, hence
fostering myelin debris phagocytosis through TREM-2b phagocytic receptor and OLG
differentiation. Gal-3 is necessary for myelin integrity and function, as evidenced by
myelin ultrastructural and behavioral studies from LGALS3−/− mice. Mechanistically,
Gal-3 enhances actin assembly and reduces Erk 1/2 activation, leading to early OLG
branching. Gal-3 later induces Akt activation and increases MBP expression, promoting
gelsolin release and actin disassembly and thus regulating OLG final differentiation.
Altogether, findings indicate that Gal-3 mediates the glial crosstalk driving OLG
differentiation and (re)myelination and may be regarded as a target in the design of
future therapies for a variety of demyelinating diseases.
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INTRODUCTION
Galectins (Gals) constitute a 15-member family of β-galactoside-binding lectins which recognize
N-acetyllactosamine and, despite lacking specific receptors, form multivalent complexes with
cell surface glycoconjugates containing suitable oligosaccharides and trigger intracellular signals
to regulate cell survival and differentiation (Rabinovich et al., 2007; Yang et al., 2008). Among
Abbreviations: APC, adenomatous polyposis coli; CC, corpus callosum; CNPase, 2′, 3′-Cyclic-nucleotide 3′-
phosphodiesterase; EGFR, epidermal growth factor receptor; GFAP, glial fibrillary acidic protein; IFN, interferon;
IGF-1, insulin-like growth factor-1; LPS, lipopolysaccharide; MBP, myelin basic protein; mTOR, mammalian target of
rapamycin complex; NG2, neural/glial antigen 2; Olig, oligodendrocyte transcription factor; PDGFRα, platelet-derived
growth factor receptor α; PLP, myelin proteolipid protein; TGF, transforming growth factor; TNF, tumor necrosis factor;
TREM-2, triggering receptor expressed on myeloid cells-2.
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Gals, Gal-1, -8, and -9 exert similar immunosuppressive and
anti-inflammatory effects on the pathogenesis of demyelinating
diseases such as Multiple Sclerosis (MS) and its experimental
models (Anderson et al., 2007; Toscano et al., 2007; Starossom
et al., 2012; Rinaldi et al., 2016; Pardo et al., 2017). In contrast, the
role of Gal-3 seems to be more complex and even controversial.
In this context, the present review firstly summarizes
Gal-3 structure, location in cells and tissues, extracellular and
intracellular space functions, regulation, internalization and
secretion. The manuscript then focuses on the current knowledge
of Gal-3 role in central nervous system (CNS) health and disease,
particularly regarding oligodendrocyte (OLG) differentiation,
myelination and remyelination, and its potential as a target in the
design of future therapies for a variety of demyelinating diseases.
Gal-3 Structure
Gal-3 is a 25–35 KDa unique protein from the evolutionarily
conserved family of Gals, which share a carbohydrate-
recognition domain (CRD) and bind to β-galactoside-containing
glycoconjugates. Gals are classified into three groups on the basis
of their structural architecture: proto, chimera and tandem types,
with Gal-3 being the only representative of the chimeric type
(Barondes et al., 1994). Gal-3 has three structural domains: (a)
the NH2 terminal domain containing serine phosphorylation
sites Ser6 and Ser12, important for nuclear localization and
oligomerization; (b) a proline and glycine-rich collagen-like
sequence susceptible to metalloprotease (MMP) cleavage; and (c)
a COOH terminal domain containing the CRD and the NWGR
anti-death motif, highly conserved within the BH1 domain of
the Bcl-2 protein family (Dumic et al., 2006; Funasaka et al.,
2014). In the presence of ligand galactose, Gal-3 is able to form
pentamers whose affinity increases when galactose binds other
saccharides like N-acetyllactosamine (Hirabayashi et al., 2002;
Ahmad et al., 2004).
Gal-3 Tissue and Cellular Localization
Gal-3 is a ubiquitously distributed protein in adult tissue
but has a tissue-time-dependent expression pattern throughout
mouse embryogenesis (Poirier and Robertson, 1993; Fowlis
et al., 1995; Van den Brule et al., 1997). In terms of cell
populations, Gal-3 expression has been detected in fibroblasts,
chondrocytes, osteoblasts, osteoclasts, keratinocytes, Schwann
cells, gastric mucosa and endothelial cells from various tissues
and organs (reviewed by Dumic et al., 2006). In addition
to reports on neuronal and glial expression (Yoo et al.,
2017), Gal-3 has been shown expressed in vivo by astrocytes
in the subventricular zone (SVZ), being indispensable for
cytoarchitecture maintenance but dispensable for apoptosis and
proliferation (Comte et al., 2011). Gal-3 also maintains cell
motility toward the olfactory bulb, possibly through EGFR
phosphorylation modulation (Comte et al., 2011). Abundant
evidence shows Gal-3 expression in cells committed to the
immune response such as neutrophils, eosinophils, basophils,
mast cells, Langerhans cells, dendritic cells, monocytes and
macrophages from different tissues (Holíková et al., 2000; Jin
et al., 2005; Chen et al., 2006; Sundblad et al., 2011; Novak
et al., 2012; Ge et al., 2013; Wu et al., 2017; Brittoli et al., 2018).
Even in cell types which do not normally express it such as
lymphocytes, Gal-3 expression can be induced by various stimuli
like T-cell receptor ligation, viral transactivating factors, and
calcium ionophores (Hsu et al., 2009). Gal-3 is also expressed
in several types of tumors, with expression intensity depending
on tumor progression, invasiveness and metastatic potential
(Danguy et al., 2002; reviewed in van den Brule et al., 2004).
Regarding intracellular localization, Gal-3 is found in both cell
cytoplasm and nucleus (Haudek et al., 2010) and is secreted
to the extracellular space where it is often incorporated to
the extracellular matrix (ECM) (Krzes´lak and Lipin´ska, 2004).
Worth pointing out, Gal-3 functions are tightly dependent on
localization.
Gal-3 Functions
A summary of Gal-3 functions in the extracellular and
intracellular space, its regulation and its internalization and
secretion is provided in Figure 1.
Extracellular Space
As it lacks a secretion signal sequence, Gal-3 is secreted
via a non-classical pathway (described in Gal-3 secretion and
internalization). It is often incorporated to the ECM to modulate
cell adhesion or interact with plasmatic membrane receptors by
binding to carbohydrate moieties in an autocrine or paracrine
fashion to form membrane lattices and trigger intracellular
events. Gal-3 impact on cell adhesion and migration depends on
its multivalent capacity, as it functions as a nexus between ECM
and membrane receptors and can thus inhibit or potentiate these
cell properties. Gal-3 binds laminin, hensin, elastin, collagen
IV, tenascin-C and -R, and crosslinks with integrins, the major
cell adhesion receptor modulators (reviewed by Dumic et al.,
2006). Regarding membrane receptors, those having five or more
glycosylated sites are preferable candidates for lattice formation,
like TGFβR and EGFR, while those with fewer glycosylation sites
are below the threshold. This scenario may change, however,
when N-glycosylation is stimulated with UDP-GlcNAc (Lau
et al., 2007; Nabi et al., 2015). Extracellular Gal-3 has been
described mainly as an inflammatory mediator: for example,
it is chemoattractant to monocytes, increases superoxide anion
production in monocytes and neutrophils, increases apoptosis
in T-cells and other cell types depending on the doses used,
increases LPS responses and decreases T-cell receptor (TCR)-
mediated signaling in T-cells, among other functions (Hsu et al.,
2009; Dabelic et al., 2012; Xue et al., 2017; Uchino et al.,
2018). Also, depending on cell types, extracellular Gal-3 can
promote or inhibit cell proliferation and growth (Krugluger
et al., 1997; Inohara et al., 1998; Diao et al., 2018; Zhou et al.,
2018).
Intracellular Space
Within the cell, Gal-3 is distributed between the cytoplasm and
the nucleus depending on cell types and conditions (Haudek
et al., 2010). In the intracellular compartment most Gal-3
binding appears to be mediated by protein–protein interaction
rather than protein-carbohydrate recognition. In the cytoplasm,
it plays an anti-apoptotic role, as it interacts with Bcl-2, and
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 September 2018 | Volume 12 | Article 297
fncel-12-00297 September 10, 2018 Time: 17:35 # 3
Thomas and Pasquini Galectin-3 and Oligodendroglial Biology
FIGURE 1 | (A) Extracellular space: Gal-3 either binds to the ECM compounds (laminin, hensin, elastin, collagen IV, tenascin-C and -R, and integrin) to modulate cell
adhesion, or interacts with plasmatic membrane receptors by binding to carbohydrate moieties in an autocrine or paracrine fashion to form membrane lattices and
trigger intracellular events. Intracellular space: within the cell, Gal-3 is found in both cytoplasm and nucleus, and its binding appears to be mediated by
protein-protein interactions. In the cytoplasm, it plays an anti-apoptotic role (Bcl-2), and modulates signaling pathways (Akt and in Erk 1/2) to promote or inhibit cell
growth, proliferation and differentiation. In the nucleus, Gal-3 is crucial for pre-mRNA splicing (spliceosome incorporation) and to promote or repress transcription.
Internalization and secretion: Gal-3 enters the cell by non-clathrin-mediated endocytosis and goes through endosomal organelles to be later sorted elsewhere or
degraded. Gal-3 is secreted via a non-classical pathway and apparently through exosomes. (B) Regulation: Gal-3 activity is regulated by MMP2 and MMP9 cleavage
(Ala62 to Tyr63), generating a 22 kDa whole CRD peptide (high affinity for carbohydrates) and a 9 kDa N-terminal peptide (oligomerization capacity). Also, Gal-3 is
phosphorylated in Tyr residues by c-Abl kinase to promote its own degradation in lysosomes in Ser residues by casein kinase I to reduce its carbohydrate binding
capacity, and by GSK3-β to regulate the Wnt-β-catenin pathway.
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it also modulates signaling pathways in order to promote or
inhibit cell growth, proliferation and differentiation. It activates
Akt (Kariya et al., 2018; Ruvolo et al., 2018), inhibits or
activates Erk 1/2 (Alge-Priglinger et al., 2011; Mori et al., 2015;
Zhang et al., 2017), and increases β-catenin levels (Shimura et al.,
2004; Hu et al., 2015), among other functions, depending on
the cell types evaluated. In the nucleus, Gal-3 is crucial for
pre-mRNA splicing, as it is incorporated into spliceosomes by
associating with the U1 small nuclear ribonucleoprotein (snRNP)
complex (Patterson et al., 2002; Haudek et al., 2010). Gal-3 has
also been shown to promote or repress the transcription of certain
genes (Krugluger et al., 1997; Iacobini et al., 2017; Zhou et al.,
2018).
Gal-3 Regulation
Gal-3 is regulated mainly by degradation by MMPs,
phosphorylation and space-time coordinated expression, as
described above. Aminoacid sequence analyses have revealed
that Gal-3 is cleaved by MMP2 and MMP9 between Ala62 and
Tyr63, resulting in two peptides: a 22 kDa peptide containing the
whole CRD and a 9 kDa N-terminal peptide (Gao et al., 2017).
The CRD peptide retains its carbohydrate-binding activity
with increased affinity for carbohydrates (Ochieng et al.,
1994). However, Gal-3 capability to oligomerize is lost upon
cleavage, which generates changes in Gal-3 functions such as
the interaction with membrane receptors (Nabi et al., 2015).
Therefore, Gal-3 cleavage by MMP is of high importance to
determine its activity. Also worth noticing, Gal-3 induces the
expression and secretion of MMP9 in melanoma cells, indicating
a feedback loop for Gal-3 regulation (Mauris et al., 2014;
Dange et al., 2015). Also, in other cell types, Gal-3 is known
to be phosphorylated in Tyr residues by c-Abl kinase (Balan
et al., 2010) to promote its own degradation in lysosomes (Li
et al., 2010), in Ser residues by casein kinase I to reduce its
carbohydrate binding capacity (Mazurek et al., 2000), and by
GSK3-β to regulate the Wingless (Wnt)-β-catenin pathway (Song
et al., 2009).
Gal-3 Internalization and Secretion
It is known that Gal-3 is incorporated into the cell through
non-clathrin-mediated endocytosis and goes through endosomal
organelles to be later sorted elsewhere or degraded (Hönig et al.,
2015; Nabi et al., 2015). Regarding externalization, Gal-3 lacks a
signal for classical externalization and it was recently found in the
lumen of apical secreted exosomes from epithelial cells. For this
type of secretion, Gal-3 release depends on the endosomal sorting
complex required for transport I, essential for cargo recruitment
(Bänfer et al., 2018). This notion is of great relevance for further
exploration, as exosomes are being increasingly described as a
short and long-distance communication pathway between cells.
However, the mechanisms, if any, through which Gal-3 can be
released out of exosomes and into the extracellular space in a free
form remain to be elucidated.
Gal-3 Roles in Non-Cns Disease
Secreted Gal-3 is currently under evaluation as a biomarker of
tumoral and fibrotic processes, as it has been found elevated
in many cancers including solid tumors and blood cancers like
leukemias and lymphomas (reviewed in Ruvolo, 2016). Gal-3 is
thought to be produced by tumor microenvironment cells such
as mesenchymal stromal cells and to play immunosuppressive
functions, thus supporting metastasis (Ruvolo, 2016). Gal-3 also
takes part in tumor cell adhesion, proliferation, differentiation,
angiogenesis, and metastasis (Wang and Guo, 2016). In fibrotic
processes, Gal-3 has been principally described in skin illnesses
(McLeod et al., 2018) and liver and heart failure (Moon et al.,
2018; Piek et al., 2018). In acute ischemic stroke, higher levels
of serum Gal-3 have been recently associated with increased
death risk (Wang et al., 2018). Likewise, it is extensively
described in inflammatory processes modulating macrophage
responses (de Oliveira et al., 2015; Mietto et al., 2015; Schnaar,
2016). In addition, Gal-3 seems to exert an inhibitory effect on
LPS-induced inflammation, as increased inflammatory cytokine
production is induced in both LGALS3−/− macrophages and
wild-type macrophages in which Gal-3 binding has been
neutralizated through antibodies. This was also supported by an
increase in LGALS3−/− mice vulnerability to LPS, reflected by
higher inflammatory cytokine and nitric oxide production (Li
et al., 2008).
GAL-3 IN HEALTHY OLG
DIFFERENTIATION
Having introduced the main features of Gal-3, the present review
will now focus on the current knowledge of Gal-3 role in CNS
myelination, remyelination and OLG differentiation (Figure 2).
Gal-3 Expression and Regulation in OLG
Oligodendrocyte are resident CNS cells in charge of myelination,
i.e., the physiological process of axon insulation allowing
metabolic and trophic support for axons and providing a
rapid saltatory conduction of action potentials (Bercury and
Macklin, 2015). In terms of morphological and molecular
stages, OLG are initially bipolar cells named oligodendrocyte
progenitor cells (OPC) which proliferate and migrate, expressing
molecular markers like PDGFRα and NG2. An intermediate stage
represented by pre-OLG, more ramified, express CNPase, Olig 1
and O4, among others. These cells later form myelin membranes
and express MBP, APC, and PLP, hence becoming the fully
mature OLG capable of myelination (Nave and Werner, 2014;
Snaidero and Simons, 2017).
Gal-3 mRNA expression has not yet been evaluated in
OLG, which makes it still uncertain whether it is actually
expressed in this cell type and whether it acts in an autocrine
fashion to regulate OLG maturation. However, Gal-3 has been
immunocytochemically detected in immature (PDGFRα, A2B5,
and O4) and mature (O1, MBP, CNPase, PLP) OLG isolated
from primary rat cultures, with higher levels in mature ones
(Pasquini et al., 2011). Recent work also outlines Gal-3 occasional
expression by Rip+ OLG in white matter from normal rat brains
(Yoo et al., 2017). Gal-3 appears to be cleaved in OPC by MMP2
and then stabilized in mature OLG, which suggests variations in
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FIGURE 2 | Extracellular Gal-3 drives OLG differentiation and (re)myelination: Gal-3 is expressed in microglial cells during remyelination, favoring an M2 microglial
phenotype and, therefore, fostering myelin phagocytosis through TREM-2b phagocytic receptor and OLG differentiation probably by IGFR-1 pathway stimulation. In
OPC (i), Gal-3 drives early process outgrowth through enhanced actin assembly and a decrease in Erk 1/2 activation, and later regulates OLG maturation (ii) by
inducing Akt activation and inhibiting β-catenin degradation to increase MBP expression and promotes gelsolin release and actin cytoskeleton disassembly. Also,
microglia-released Gal-3 induces OLG fate in neural stem cells. Finally, Gal-3 promotes neurite outgrowth but exerts both deleterious and protective effects on
neuronal death in ischemic brain injury.
its biological activity during OLG differentiation (Pasquini et al.,
2011).
Gal-3 Drives OLG Maturation
As part of pioneering studies on the direct influence of
Gal-3 on OLG maturation, in 2011 our group demonstrated
that extracellular Gal-3 promotes OLG differentiation and
may be expressed and secreted by microglia (Pasquini et al.,
2011). Microglia are known to express Gal-3 in normal
oligodendrogenesis (Ellison and de Vellis, 1995; Pasquini
et al., 2011) and upon activation, promoting myelin debris
phagocytosis through FcγR, CR3/MAC-1 and SRAI/II receptors
and fostering remyelination upon injury or disease (Rotshenker
et al., 2008). Work by Pasquini et al. (2011) has revealed
that extracellular Gal-3 promotes dose-dependent OLG
differentiation in close relationship with the glycoconjugates
present in OPC cell surfaces. Glycosylation signature analysis has
shown that OPC possess a permissive glycophenotype expressing
the necessary carbohydrates for Gal-3 binding. In contrast,
Gal-3 overexpression in the OLG N20.1 cell line produces no
changes in MBP promoter activity, which indicates that changes
in endogenous Gal-3 relative abundance do not affect OLG
differentiation. Moreover, treatment with conditioned media
from wild type (WT) microglia, but not LGALS3−/− microglia,
promotes OLG differentiation, suggesting that microglia express
the Gal-3 necessary to induce OLG maturation. In addition,
using neurosphere cultures, our group has also proven Gal-3 to
promote cell commitment toward the OLG lineage (Pasquini
et al., 2011).
Gal-3 Accelerates OLG Differentiation:
Actin Cytoskeleton Dynamics
Modulation
Although studies on the processes controlling signaling pathways
and cytoskeleton dynamics in OLG have rendered contrasting
results, recent thorough reports proposed a two-step model for
actin dynamics in OLG: first, pro-assembly dynamics until OLG
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are fully differentiated and, second, a switch to pro-disassembly
dynamics to start myelination (Nawaz et al., 2015; Zuchero
et al., 2015). This is driven by interplay between MBP and actin
disassembly proteins like cofilin-1 and gelsolin, both sequestered
and hence inactivated by phosphatidylinositol 4,5-bisphosphate
(PIP2) on the plasma membrane. When MBP is expressed as
OLG reach their final maturational state, MBP competes for
PIP2 binding, and gelsolin and cofilin-1 are displaced from their
binding to the inositol and activated to drive actin disassembly
(Zuchero et al., 2015). Further work has demonstrated that
cytoplasmic gelsolin is crucial for OPC differentiation and
is a downstream effector of anti-LINGO1 blocking antibody.
This study also shows that cytoplasmic gelsolin expression
drives OPC differentiation and increases as OLG mature,
indicating that cytoskeleton severing proteins are crucial for
morphological changes required for OLG differentiation (Shao
et al., 2017). Gal-3 effects on the actin cytoskeleton appear
to be cell type-dependent, driving cytoskeleton disassembly
dependent on Erk 1/2 inactivation in retinal pigment epithelium
(RPE) cells (Alge-Priglinger et al., 2011), while promoting
lamellipodia formation in epithelial cells (Saravanan et al.,
2009).
In the B16F10 murine melanoma cell line, cells plated over
Gal-3 as substrate have shown increased actin turnover and
lamellipodia formation on the cell edges, and an increase
in Rac1 activation (More et al., 2016). Indeed, our most
recent work first unveiled the role of extracellular Gal-3 in
OLG cytoskeleton dynamics (Thomas and Pasquini, 2018). Our
group demonstrated that extracellular Gal-3 modulates actin
cytoskeleton dynamics in primary rat OLG cultures in two
steps: first, Gal-3 drives actin polymerization dynamics and then
switches to depolymerization dynamics, which may be thought
of as an accelerated version of the process described by Zuchero
et al. (2015). These changes are accompanied by an increase in
gelsolin and MBP expression, generating actin disassembly in
a carbohydrate-dependent manner as OLG mature. Moreover,
Gal-3 induces an increase in the expression of actin ADT-ATP
exchanger profilin-1 and activated small GTPase Rac-1, further
supporting its crucial role in actin dynamics. Likewise, Gal-3
accelerates OLG differentiation as compared to vehicle-treated
cells, as supported by the increase observed in CNPase+ cells
and in the area and expression of MBP (Thomas and Pasquini,
2018).
Gal-3 Accelerates OLG Differentiation:
Underlying Signaling Pathways
Conserved signaling pathways in OLG like Erk 1/2, β-catenin
and Akt play an important, though controversial, role in OLG
maturation.
Erk 1/2
Some in vitro reports have shown Erk 1/2 inhibition to diminish
OLG maturation (Fyffe-Maricich et al., 2011; Guardiola-Diaz
et al., 2012; Xiao et al., 2012), while other studies in vivo and
in vitro have reported no changes upon Erk 1/2 inactivation
in OPC differentiation (Ishii et al., 2012, 2013; Xiao et al.,
2012). Also, inhibiting Erk 1/2 decreases OPC proliferation in
response to growth factors (Bhat and Zhang, 1996; Kumar et al.,
1998; Baron et al., 2000; Bansal et al., 2003; Cui and Almazan,
2007; Frederick et al., 2007). Erk 1/2 has been proposed to
contribute to the passage from OPC to pre-OLG (Narayanan
et al., 2009; Guardiola-Diaz et al., 2012), while other reports
claim that it promotes the passage from pre-OLG to mature OLG
(Tyler et al., 2009; Bercury et al., 2014). A thorough revision
of the involvement of Erk 1/2 signaling in CNS myelination
has been recently published by Gonsalvez et al. (2016). In
addition, work by More et al. in 2016 revealed that tumor
cells plated on Gal-3 show a time-dependent decrease in Erk
1/2 phosphorylation. Similarly, extracellular Gal-3 decreases Erk
1/2 activation in RPE cells (Alge-Priglinger et al., 2011) and
in keratinocytes, generating anti-apoptotic events (Larsen et al.,
2011). Our recent work indicates that Gal-3 inhibits Erk 1/2
in a carbohydrate-dependent manner, thus contributing to the
promotion of MBP and gelsolin expression and subsequent OLG
maturation (Thomas and Pasquini, 2018).
Akt/mTOR
The role of the Akt/mTOR pathway is less controversial than
that of Erk 1/2, as it is known to improve myelination both
in vitro and in vivo. However, as with Erk 1/2, the timing of Akt
action has not fully elucidated yet, although available evidence
suggests that it favors the passage from pre-OLG to OLG, in
a close crosstalk with Erk 1/2 (reviewed in Gaesser and Fyffe-
Maricich, 2016). In vivo, Akt overexpression as well as PTEN
inhibition generates a hypomyelinated phenotype (Flores et al.,
2008; Narayanan et al., 2009). mTOR is known to promote lipid
synthesis by activating SREBPS, which is of high importance
in promoting myelin synthesis (reviewed in Figlia et al., 2018).
Further support for the pro-myelinating role of mTOR has
been obtained through the use of rapamycin, mTOR inhibitor,
revealing that mTOR is crucial for OPC differentiation, and
myelin protein and mRNA synthesis (Tyler et al., 2009, 2011;
Guardiola-Diaz et al., 2012).
Several authors have demonstrated that Gal-3 activates
Akt signaling. In human cutaneous squamous cell carcinoma
tissues, Gal-3 binds to β4-integrin and activates the Akt
axis (Kariya et al., 2018). Also, in mammary epithelial
tumor cells, extracellular Gal-3 activates PI3K, upstream
kinase in the Akt pathway (Lagana et al., 2006). In tumor
cell line B16F10, Akt phosphorylation increases with time
in cells plated on Gal-3 as substrate (More et al., 2016).
In line with these results, our work proves that Gal-3
augments Akt activation also in a carbohydrate-dependent
fashion, which leads to an increase in MBP and gelsolin
expression, driving OPC differentiation (Thomas and Pasquini,
2018).
β-catenin
β-catenin is a protein degraded by the proteasome when
phosphorylated by a destruction complex in the cytoplasm, an
event which requires absence of Wnt ligand binding to Frizzled
receptor. When binding occurs, β-catenin is not degraded and
can translocate to the nucleus where it acts as a transcription
factor modulating cellular functioning. In OLG, some authors
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describe this pathway as an OLG differentiation inhibitor (Fancy
et al., 2009; Feigenson et al., 2009; Ye et al., 2009), while others
describe it as promoting OLG differentiation (Kalani et al., 2008;
Tawk et al., 2011; Ortega et al., 2013). These differences probably
respond to the conditions used and the timing of evaluation.
In colon cancer cells, Gal-3 has been shown to drive β-catenin
accumulation by regulating GSK-3β phosphorylation –a member
of β-catenin destruction complex– via the PI3K/Akt pathway
(Song et al., 2009). A similar conclusion has been reached in
gastric cancer cells, where absence of Gal-3 diminishes β-catenin
levels (Kim et al., 2010). Our results show that Gal-3 augments
β-catenin expression in mature OLG, concomitantly with an
increase in MBP expression and Akt activation. β-catenin levels
decrease when Akt is inhibited, further supporting the close
connection between these pathways (Thomas and Pasquini,
2018).
Gal-3 Drives Axon Myelination and
Neurite Outgrowth
To investigate Gal-3 in vivo role during the myelination process,
our group has analyzed Gal-3 expression at postnatal day 5 (P5),
10 (P10), 15 (P15), and 20 (P20) using transgenic mice expressing
the enhanced green fluorescent protein (EGFP) driven by the
promoter of oligodendroglial protein CNPase (CNP–EGFP).
Gal-3 expression showed substantial changes during white matter
development, with high expression levels at P5 and a reduction
upon myelin development. In agreement, high levels of Gal-3
were found at P5 in microglial cells localized in the CC and
cingulum, fairly close to CNPase+ cells. Interestingly, confocal
microscopy showed some CNPase+ cells with maturen OLG-
like morphology to colocalize with Gal-3. On the other hand,
Gal-3 was detected at low levels in astrocytes at P10 and P15,
and at high levels in the SVZ at all ages evaluated. This work
also revealed a critical role for Gal-3 during OLG myelination,
as reflected by the morphological changes observed in the myelin
of LGALS3−/− mice. These animals presented hypomyelination
in the striatum and CC, as revealed by electron microscopic
morphometric analysis. These myelin defects were deeper in
8-week-old relative to 4-week-old mice. Also, myelin showed
lesser integrity and abnormal compaction compared to WT mice.
Furthermore, LGALS3−/− mice exhibited substantial alterations
in behavior with diminished levels of innate anxiety than their
WT littermates (Pasquini et al., 2011).
Interestingly, substratum-bound Gal-3 had been previously
shown to promote outgrowth of neurites from dorsal root
ganglia explants (Pesheva et al., 1998) and neurite stabilization
in the cerebellum (Mahoney et al., 2000). In this context,
further work needs to be carried out in order to elucidate
Gal-3 role in myelination in vivo and whether this neurite
outgrowth and stabilization could influence OLG myelin
formation capacity.
GAL-3 IN CNS DISEASE
The main features of Gal-3 in CNS diseases are summarized in
Figure 2.
Inflammation and Hypoxic-Ischemic
Injury
In CNS disease, Gal-3 has been attributed both deleterious and
protective effects, being mainly expressed by activated microglia
and upregulated by inflammatory stimuli (Umekawa et al., 2015).
In a focal cerebral ischemia model in mice, Gal-3 was found
to mediate microglial activation and proliferation and to be
preferentially expressed by a subgroup of proliferating IGF-
1-expressing microglia. Tunicamycin-mediated inhibition of
N-glycosylation diminishes IGF-1-induced microglial mitogenic
response, while coimmunoprecipitation assays have revealed Gal-
3 binding to IGF-receptor 1, which suggests that interactions
between Gal-3 and N-linked glycans present in growth factor
receptors are mediators of IGF-receptor 1 (IGF-R1) signaling
(Lalancette-Hébert, 2007; Rotshenker, 2009; Lalancette-Hébert
et al., 2012). Moreover, an increase in Gal-3 expression
is observed in several ischemic models, associated to an
improvement in neurologic function, a reduction in neuronal
cell death, angiogenesis, proliferation of neuronal precursors,
and a type 2 T cell immune bias (Ohtaki et al., 2008; Yan
et al., 2009). These findings suggest that Gal-3 may act as an
important modulator of the brain inflammatory response with
high neuroprotective potential. However, in other models of
hypoxic-ischemic (HI) injury, Gal-3 has been shown to exert
deleterious effects. For instance, LGALS3−/− mice are protected
from neuronal death in the hippocampus and striatum, and
a reduction in Gal-3 is observed during delayed neuronal
death induced by hypothermia or antiapoptotic agents in the
CA1 region (Doverhag et al., 2010; Satoh et al., 2011a,b;
Hisamatsu et al., 2016). Further studies have also shown that
the increase in Gal-3 expression observed in ischemia is blocked
when antiapoptotic molecule Bis is downregulated, generating
less vulnerable hippocampal neurons (Cho et al., 2012). In
addition to the deleterious effects, Gal-3 has been suggested
as a target for the treatment of post-stroke gastrointestinal
complications, as it is released after stroke and triggers central
and peripheral enteric neuronal loss through a TLR4-mediated
mechanism involving TAK1 and AMPK (Cheng et al., 2016).
Finally, recent studies conclude that Gal-3 is necessary for
angiogenesis after ischemia but does not affect apoptosis,
infarct size, microglial, and astrocyte activation/proliferation,
SVZ neurogenesis or migration to lesion (Young et al., 2014; Xu
et al., 2017).
Amyotrophic Lateral Sclerosis,
Alzheimer’s Disease, Parkinson’s
Disease and Prions
In amyotrophic lateral sclerosis (ALS), advanced glycation end-
products (AGE) are a source of inflammation and oxidative
injury. Gal-3 acts as an AGE receptor and leads them to
lysosome degradation and removal (Pricci, 2000). In line
with this, Gal-3 counteracts neuroinflammation, as its deletion
leads to heightened neurodegeneration in ALS owing to
AGE accumulation (Lerman, 2012). Moreover, Gal-3 has
emerged as a key biomarker candidate on account of its
differential expression in ALS mouse model SOD1 (G93A)
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and spinal cord tissue and cerebrospinal fluid from ALS
patients (Zhou et al., 2010). Its expression is also increased in
microglia accompanied by osteopontin and vascular endothelial
growth factor (VEGF), concomitantly with low expression of
TNFα, IL-6, brain-derived neurotrophic factor (BDNF) and
arginase-1 from ALS rat model SOD1 (G93A) (Nikodemova
et al., 2014). Gal-3 might also be postulated as a potential
biomarker for Alzheimer’s disease (AD), as AD patients exhibit
significantly higher levels of serum Gal-3 (Wang et al., 2015).
In Parkinson’s disease (PD), extracellular α-synuclein-aggregate-
induced inflammation can be reduced by Gal-3 inhibition,
which suggests therapeutic potential for Gal-3 (Boza-Serrano
et al., 2014). In addition, microarray analysis of substantia nigra
in a PD animal model has shown the temporal expression
profiles of 4 candidate genes implicated in neuroglial activation
and functional maturation, i.e., Gal-3, Heat shock protein 27,
Lipocalin 2 and Tissue inhibitory metalloproteinase 1 (Choy
et al., 2015). In prion-infected brain tissue, Gal-3 has been
found to exert harmful effects (Riemer et al., 2004; Mok et al.,
2006, 2007), as its expression in activated microglia/macrophages
correlates with abnormal prion protein accumulation (Jin et al.,
2007).
MS and Its Experimental Models
Oligodendroglial injury leads to demyelination, which is followed
by a regenerative response consisting in the formation of new
myelin sheaths –a process called remyelination (Franklin, 2002;
Franklin and Ffrench-Constant, 2017). This process has been
described in animal models and in human demyelinating diseases
such as MS (Prineas et al., 1993; Patrikios et al., 2006; Patani
et al., 2007). MS course varies considerably among patients,
although the most frequent presentation consists of recurring
clinical symptoms followed by total or partial recovery, namely
the classic relapsing-remitting form of MS. After 10–15 years
of disease, symptoms become progressive in up to 50% of
untreated patients and lead to clinical deterioration for several
years, a stage referred to as secondary progressive MS. In about
15% of MS patients, however, disease progression is relentless
as from onset, in what constitutes primary progressive MS
(Bjartmar et al., 2001; McFarland and Martin, 2007; Tallantyre
et al., 2010). The progressive stage is in part due to incomplete
remyelination, which produces the loss of axonal metabolic
support provided by myelin and concomitant axonal and
neural degeneration, which lead to the progressive disability
observed in the later stages of MS (Nave, 2010; Franklin et al.,
2012).
Sera from patients with secondary progressive MS has
been recently shown to present auto-antibodies against
Gal-3, which may be responsible for blood brain barrier
progressive damage (Nishihara et al., 2017). These authors
determined that membrane-bound Gal-3 in human brain
microvascular endothelial cells (BMEC) is a target for auto-
antibodies present in secondary progressive MS serum but
not for healthy donors or patients with other CNS illnesses;
downregulation of Gal-3 in these cells causes an increase in
the expression of intracellular adhesion molecule-1 (ICAM-
1) and phospho-NFκB p65, both molecules described as
responsible for leukocyte leakage to the CNS (Dietrich,
2002). These effects are also observed when BMEC are
incubated with secondary progressive MS serum but prevented
when Gal-3 is downregulated in BMEC or when secondary
progressive MS serum is depleted from anti-Gal-3-auto-
antibodies. These results hint at Gal-3 and anti-Gal-3
antibodies as therapeutic targets to prevent blood brain
barrier damage.
Further work has described the effect of cerebrospinal
fluid (CSF) from patients with primary progressive MS or
relapsing remitting MS in the morphology and transcriptional
response of treated OPC (Haines et al., 2015). The results
obtained indicate that OPC treated with primary progressive
MS CSF present a significantly more ramified morphology
than control or relapsing remitting MS CSF, accompanied by a
pro-differentiating transcriptome: downregulation of PDGFRα
and LINGO1 genes and upregulation of MAG gene. However,
this transcriptome is different from that present in normal
OPC differentiation. Interestingly, this work reports LGALS3
gene upregulation only in primary progressive MS CFS-treated
OPC and establishes a link between Gal-3 upregulation and
increased OPC branching. Gal-3 upregulation has also been
observed in post-mortem human brain tissues with primary
progressive MS.
Taken together, these findings indicate that Gal-3 is a positive
target for OLG differentiation in human MS tissue and drives
the downregulation of ICAM-1 in BMEC, mediating a protective
effect on the blood–brain barrier. However, the presence of
anti-Gal-3 auto-antibodies is responsible for blood brain barrier
damage, a negative effect which might be counteracted through
neutralizating therapy.
Current evidence has proposed exosomes as possible
biomarkers and therapeutic agents in CNS disease. Most
importantly, as therapeutic agents, exosomes display some
advantages, as they can deliver cargo to other cells, rapidly
pass the brain–blood barrier and render low immunogenicity
(Chen and Chopp, 2018; reviewed in Osier et al., 2018). As
described before in this review, Gal-3 is known to be excreted
through exosomes, which opens doors for the evaluation of the
therapeutic potential and biomarker capacity of the presence of
Gal-3 in exosomes.
Even if experimental models fail to replicate MS in its
full complexity and heterogeneity, they have succeeded in
developing various treatments for MS patients. Several well-
established experimental demyelination models include those
mediated by immunity, virus and toxins. The most widely
used animal model of CNS demyelination is experimental
autoimmune encephalomyelitis (EAE), in which mice are
immunized with myelin oligodendroglial glycoprotein. EAE
constitutes the most widely exploited model and is especially
useful to study the autoimmunity aspects in MS pathology.
However, numerous therapeutic agents displaying beneficial
effects in this model have proven poorly or not beneficial at
all in the treatment of MS. LGALS3−/− mice display clearly
diminished CNS macrophage infiltration during EAE, which
leads to lesser disease severity (Jiang et al., 2009). These findings
suggest a central role of Gal-3 in promoting inflammation
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by leukocyte recruitment. In addition, Gal-3 is induced in
several cell types involved in damaged axon and cell debris
removal and axon regeneration and remyelination, which hints
at neuroprotective role of Gal-3 in EAE mice (Itabashi et al.,
2018).
Virus-induced demyelination models support the hypothesis
that some environmental factors, such as viral infections,
are involved in MS and may be actually triggering the
disease. MS-induced inflammation may decrease SVZ cell
proliferation and thus hinder repair. Gal-3 expression
increases in active human MS lesions (Stancic et al., 2011),
in periventricular regions in human MS and after murine
TMEV infection (James et al., 2016), whereas Gal-3 loss
reduces the number of immune cells in the SVZ and
restores proliferation in a viral model of MS (James et al.,
2016).
Another increasingly used and more recently described
demyelination model consists in the administration of cuprizone
(CPZ) as part of the diet of young adult mice, which produces
massive demyelination through pathogenic T cell-independent
mechanisms, with different areas specifically affected in the
CNS such as the CC (Suzuki and Kikkawa, 1969; Blakemore,
1973; Ludwin, 1978; Matsushima and Morell, 2001). CPZ-
induced demyelination is known to involve the recruitment
of resident microglia, while peripheral macrophage infiltration
seems to be still controversial (McMahon et al., 2002; Mildner
et al., 2007; Lampron et al., 2015). The CPZ model then
offers the advantage of investigating CNS processes leading
to remyelination independently of peripheral immune system
contribution, as the model keeps the blood brain barrier intact
(Bakker and Ludwin, 1987; Kondo et al., 1987).
Previous studies have described four different lesion subtypes
in MS: pattern-1 and -2 lesions are thought to be autoimmune
response-mediated, while pattern-3 and -4 lesions are regarded
as primary oligodendrogliapathy (Lucchinetti et al., 2000).
The first two types are experimentally simulated by the EAE
model, while the second two are mimicked by toxic models
such as cuprizone (CPZ) or lysolecithin (LPC) administration.
Although the established animal models have their advantages
and disadvantages, no model fully replicates the stages of MS and
they are actually complementary.
Gal-3-in the CPZ Model
Gal-3-induced microglial response modulation during
demyelination
Phagocytosis of myelin debris by microglia in CPZ demyelination
is concomitant with an increase in phagocytic receptor TREM-2b
expression (Voß et al., 2011), which seems to be key for
remyelination to occur, as oligodendroglial differentiation can
be hampered by myelin debris (Kotter et al., 2006). Strikingly,
myelin phagocytosis relies on CR3/MAC-1 and SRAI/II, in
turn regulated by Gal-3-dependent activation of PI3K; therefore,
myelin phagocytosis by LGALS3−/−microglia is usually deficient
(Rotshenker et al., 2008).
Our group has studied Gal-3 involvement in the
demyelination/remyelination process using the CPZ model
(Hoyos et al., 2014, 2016), in which 8-week-old LGAL3−/−
and WT mice were fed a diet containing 0.2% CPZ w/w for
6 weeks to evaluate demyelination, followed by two more weeks
on a CPZ-free diet to assess remyelination. Our results have
shown that CPZ-induced demyelination follows a similar course
up to the 5th week of treatment in 8-week-old LGALS3−/−
and WT mice, as demonstrated by MBP immunostaining
and electronic microscopy assessment. The OPC generated in
response to CPZ demyelination in LGALS3−/− mice display
reduced branching, which reflects diminished differentiation.
These findings are in agreement with our results showing
Gal-3 ability to induce OLG differentiation and especially those
proving that conditioned media from Gal-3-expressing microglia
promote OLG differentiation, as different from conditioned
media from LGALS3−/− microglia (Pasquini et al., 2011). WT
mice exhibit spontaneous remyelination in the 5th week of
CPZ treatment, even if the CPZ diet is kept in place until the
6th week. In contrast, LGALS3−/− mice lack this ability and
suffer steady demyelination up to the 6th week with noticeable
astroglial activation. Colocalization studies have shown that
Gal-3 expression is upregulated in microglia but not in astrocytes
during CPZ-induced demyelination. Interestingly, only WT
mice display activated microglia with ED1 (CD68) expression
and TREM-2b upregulation during CPZ-induced demyelination,
unlike CPZ-treated LGALS3−/− mice, which display more
numerous microglia with activated caspase-3. These findings
support Gal-3 as a modulator of the microglial response to favor
the onset of remyelination and OLG differentiation (Hoyos et al.,
2014).
As mentioned above, TREM-2b plays a key role in
myelin debris phagocytosis. TREM-2b loss-of-function
causes a hereditary disease called polycystic lipomembranous
osteodysplasia with sclerosing leukoencephalopathy (PLOSL), or
Nasu–Hakola disease (Hakola, 1972; Nasu et al., 1973; Paloneva
et al., 2001), which presents progressive presenile dementia
and sclerosing leukoencephalopathy driven by lower microglial
phagocytic activity (Paloneva et al., 2002). Microglial TREM-2b
expression is upregulated in inflammatory and chronic phases
of EAE and produces disease exacerbation when blocked during
the effector phase (Piccio et al., 2007). Intravenous inoculation
of TREM-2-transduced myeloid cells induces EAE amelioration
accompanied by increased myelin phagocytosis (Takahashi et al.,
2007). In parallel, CPZ-induced demyelination has also shown
a robust increase in microglial phagocytic activity associated
with the upregulation of TREM-2b and CD200R, and including
TNF-α production (Voß et al., 2011). Interestingly, our results
show LGALS3−/− mice inability to upregulate TREM-2b or
increase TNF-α production but their capacity to significantly
reduce CD200R as a response to CPZ toxicity, which suggests
that Gal-3 absence alters the microglial response against
demyelination.
Our results showing that Gal-3-deficient microglial cells
fail to induce ED1 expression are in accordance with those
by Lalancette-Hébert et al. (2012), obtained in a unilateral
transient focal cerebral ischemia model. However, and in
contrast with such results, LGALS3−/− mice submitted to CPZ-
induced demyelination exhibit higher microglial proliferation
and apoptosis, as evidenced by their increased activation of
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caspase-3, which may respond to the well-established Gal-3 anti-
apoptotic role (Yang et al., 1996).
Evidence has demonstrated that chemokine ligand 2 (CCL2 or
MCP1) could be involved in MS pathology, as its neutralization
with anti-CCL2 significantly reduces EAE relapsing severity
(Karpus and Kennedy, 1997). Our results show that CCL2 mRNA
levels remain significantly higher until the 5th week in the
CC of CPZ-treated LGALS3−/−. In contrast, WT mice display
transiently higher CCL2 mRNA levels in the 1st week of CPZ
treatment with a recovery to control values in the 2nd week,
which indicates that CCL2 mediates early microglial activation.
M2 polarization of macrophages is accompanied by a reduction
in inflammatory cytokine IL-1β, TNF-α, and CCL2 (Liu et al.,
2013). Taken together, these results could indicate that the
absence of Gal-3 prevents microglial cells from shifting to an
M2 phenotype. Indeed, the fact that M2-cell-conditioned media
enhance OLG differentiation in vitro and that M2 cell depletion
impairs OLG differentiation in vivo may indicate that M2 cell
polarization is a key factor for efficient remyelination (Miron
et al., 2013), and microglial expression of Gal-3 may hence favor
the onset of remyelination, either by inducing an M2 phenotype
or exerting a direct effect on OLG differentiation.
Gal-3 in MMP regulation during remyelination
Together with endogenous tissue inhibitors, the MMP family
of zinc-dependent endopeptidases is a key player in tissue
remodeling. MMPs can also induce myelin proteins degradation
in vitro (Chandler et al., 1995, 1996; Shiryaev et al., 2009;
Hansmann et al., 2012), and have been involved in postnatal
myelination, myelin maintenance, and remyelination (Ulrich
et al., 2006; Skuljec et al., 2011; Hansmann et al., 2012). Also,
MMP-3 can mediate mature OLG apoptosis and microglial
activation with production of microglial inflammatory cytokines
and thus exacerbation of neural cell degeneration (Kim and Joh,
2006). Our immunohistological studies have shown an increase
in MMP-3 expression and a decrease in CD45+, TNFα+,
and TREM-2b+ cells during remyelination only in WT mice,
with no changes in LGALS3−/− mice during demyelination or
remyelination. Ultrastructural studies carried out by electron
microscopy after remyelination revealed collapsed axons with
a defective myelin wrap in CC of LGALS3−/− mice but
no relevant myelin wrap disruption in sections obtained
from WT mice. Worth highlighting, a blockade in OPC
differentiation has been proposed as a possible cause for
remyelination failure in demyelinating diseases (Franklin and
Kotter, 2008; Ulrich et al., 2008). Therefore, LGALS3−/− mice
incomplete remyelination may partly respond to a failure in
OPC differentiation. These results suggest that Gal-3 impacts
remyelination through mechanisms including the tuning of
microglial cells, the modulation of MMP activity and the
induction of OLG differentiation.
Gal-3 role in behavioral alterations
CPZ-fed mice exhibit weight loss and motor and behavioral
deficits (Franco-Pons et al., 2007; Xu et al., 2009). In the case of
long-term CPZ exposure, rodents exhibit behavioral alterations
which may be thought to recapitulate psychiatric disorders
(Gregg et al., 2009; Xu et al., 2009). Neuroleptic treatment has
succeeded in ameliorating some of these symptoms (Zhang et al.,
2008; Xu et al., 2010, 2011), which suggests that long-term
CPZ exposure may replicate features associated with MS and
other white matter disorders. In this line, work by our group
has shown diminished anxiety behavior in LGALS3−/− mice,
similar to that observed in early CPZ-induced demyelination
(Pasquini et al., 2011). Interestingly, hypertensive rats used as
a spontaneous model of attention deficit hyperactivity disorder
exhibit lower expression of Gal-3 in the brain prefrontal
cortex (Wu et al., 2010). Accordingly, the lack of Gal-3 and
alterations in myelin structure in LGALS3−/− mice induces
behavioral alterations such as lower anxiety levels and spatial
working memory impairment. Also, CPZ impact on behavior
is observed earlier in LGALS3−/− mice, probably due to early
mature OLG depletion (Hesse et al., 2010; Buschmann et al.,
2012).
In our remyelination studies, a decrease in anxiety persisted
both in WT and LGALS3−/− mice after 2-week recovery, as
evidenced by higher rates of entries and more time spent in open
arms in the plus maze test. An increase was also observed in
locomotor activity counts and the number of total arm entries. In
contrast, spatial working memory showed a recovery regarding
their untreated counterparts. These data are in agreement with
previous studies (Franco-Pons et al., 2007; Xu et al., 2009;
Stancic et al., 2012) and suggest that some behavioral aspects
remain altered even when histological analyses evidence fiber
remyelination and seem to be irreversible even 2 weeks after CPZ
withdrawal.
CONCLUSION
Taken together, these reports show that Gal-3 is essential
for microglial polarization following CNS injury, while the
differences observed in Gal-3 effects on different injuries
probably respond to time- and context-dependent factors.
Rahimian et al. (2018) have recently discussed the possible
molecular mechanisms of neuroprotection mediated by Gal-
3. Firstly, oligomerized Gal-3 molecules may crosslink to
IGFR upon binding to their glycans on the surface and delay
their removal by endocytosis, which results in prolonged
microglial mitogenic signaling (Partridge et al., 2004; Lalancette-
Hébert et al., 2012). This proposed mechanism could also
act as a mediator of the beneficial effects of Gal-3 on OLG
differentiation and (re)myelination, as IGF-1 produced
by microglia inhibits OLG apoptosis during CPZ-induced
demyelination and thereby promotes remyelination (Mason
et al., 2000) and acts directly on OLG and myelination, as
shown using OLG lineage-specific IGF-1R−/− mice (Zeger
et al., 2007). Additionally, Gal-3 might mediate alternative
microglial polarization induced by IL-4, as its expression
and release are stimulated by alternative activation of
macrophages with IL-4, which then binds and crosslinks
CD98 on macrophages (Mackinnon, 2012). This could also
explain the effect of Gal-3 observed on cell fate decisions toward
the oligodendroglial lineage, as IL-4-activated microglia favor
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oligodendrogenesis, whereas IFN-gamma-activated microglia
favor neurogenesis. The effect induced by IL-4-activated
microglia is also mediated, at least in part, by IGF-I (Butovsky
et al., 2006). In addition, Gal-3 promotes the proliferation of
cultured neural progenitors and its inhibition decreases the
proliferative response of the SVZ after brain ischemia (Yan et al.,
2009).
In particular, our results have shown that Gal-3 expression
in microglial cells during CPZ-induced demyelination and upon
the onset of remyelination favors an M2 microglial phenotype
and MMP activity modulation, leading to OLG differentiation.
Furthermore, Gal-3 enhances actin assembly and reduces Erk
1/2 activation, thus driving early OLG branching. Gal-3 later
induces Akt activation and higher MBP expression, which in
turn promote gelsolin release and actin cytoskeleton disassembly,
hence regulating OLG maturation. On the whole, our studies
indicate that Gal-3 could be considered a novel extracellular
signal which drives OLG differentiation and (re)myelination
through glial cell communication and therefore a target in
the design of future therapies for a variety of demyelinating
diseases.
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